Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H12FN5O2 |
| Molecular Weight | 253.233 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC=NC2=C1N=CN2[C@@H]3O[C@H](CO)C[C@@H]3F
InChI
InChIKey=KBEMFSMODRNJHE-JFWOZONXSA-N
InChI=1S/C10H12FN5O2/c11-6-1-5(2-17)18-10(6)16-4-15-7-8(12)13-3-14-9(7)16/h3-6,10,17H,1-2H2,(H2,12,13,14)/t5-,6-,10+/m0/s1
| Molecular Formula | C10H12FN5O2 |
| Molecular Weight | 253.233 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Synthesis of fluorinated nucleosides. | 2006-07 |
|
| Determination of carrier-mediated transport of 2',3'-dideoxypurine nucleosides in the rat ileum using a bidirectional perfusion technique. | 2004-02 |
|
| A facile synthetic method for 3'-alpha-fluoro-2',3'-dideoxyadenosine. | 2003-10-21 |
|
| An industrial process for synthesizing Lodenosine (FddA). | 2003-10-21 |
|
| Synthesis of 9-(2,3-dideoxy-2-fluoro-beta-D-threo-pentofuranosyl)adenine (FddA) via a purine 3'-deoxynucleoside. | 2001-11-02 |
|
| Enhanced oral bioavailability of 2'- beta-fluoro-2',3'-dideoxyadenosine (F-ddA) through local inhibition of intestinal adenosine deaminase. | 2001-09 |
|
| High performance liquid chromatography analysis of 9-(2',3'-dideoxy-2'beta-fluoro-D-threo-penta furanosyl) adenine and its metabolite in human plasma using solid-phase extraction on a polyfluorinated reversed stationary phase. | 2001-06 |
|
| Evaluation of a fluorogenic derivatization method for the reversed-phase HPLC analysis of 2'-beta-fluoro-2',3'-dideoxyadenosine, a new anti-AIDS drug. | 2001-05 |
|
| Fluorometric determination of 2'-beta-fluoro-2',3'-dideoxyadenosine 5'-triphosphate, the active metabolite of a new anti-human immunodeficiency virus drug, in human lymphocytes. | 2001-01-01 |
|
| CycloSal-2'-ara(ribo)-fluoro-2',3'-dideoxyadenosine monophosphates--an effort to solve the structure-activity relationship of 2'-fluoro-ddA. | 1999-08-05 |
|
| cycloSal-Pronucleotides of 2'-fluoro-ara- and 2'-fluoro-ribo-2',3'- dideoxyadenosine as a strategy to bypass a metabolic blockade. | 1999-05-06 |
|
| In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine. | 1997-06 |
|
| Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 3. 6-Amino prodrugs of 2'-beta-fluoro-2',3'-dideoxyinosine. | 1996-04-12 |
|
| Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. | 1995-11 |
|
| Enhancement by hydroxyurea of the anti-human immunodeficiency virus type 1 potency of 2'-beta-fluoro-2',3'-dideoxyadenosine in peripheral blood mononuclear cells. | 1995-07-17 |
|
| Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs. | 1991-05 |
|
| Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV. | 1990-03 |
|
| Investigations on the anti-HIV activity of 2',3'-dideoxyadenosine analogues with modifications in either the pentose or purine moiety. Potent and selective anti-HIV activity of 2,6-diaminopurine 2',3'-dideoxyriboside. | 1988-04-01 |
|
| Synthesis and anti-HIV activity of various 2'- and 3'-substituted 2',3'-dideoxyadenosines: a structure-activity analysis. | 1987-11 |
|
| 2',3'-Dideoxy-2'-fluoro-ara-A. An acid-stable purine nucleoside active against human immunodeficiency virus (HIV). | 1987-09-01 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:06:59 GMT 2025
by
admin
on
Mon Mar 31 18:06:59 GMT 2025
|
| Record UNII |
3WB2LGT4R1
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1556
Created by
admin on Mon Mar 31 18:06:59 GMT 2025 , Edited by admin on Mon Mar 31 18:06:59 GMT 2025
|
||
|
NCI_THESAURUS |
C97452
Created by
admin on Mon Mar 31 18:06:59 GMT 2025 , Edited by admin on Mon Mar 31 18:06:59 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
110143-10-7
Created by
admin on Mon Mar 31 18:06:59 GMT 2025 , Edited by admin on Mon Mar 31 18:06:59 GMT 2025
|
PRIMARY | |||
|
3WB2LGT4R1
Created by
admin on Mon Mar 31 18:06:59 GMT 2025 , Edited by admin on Mon Mar 31 18:06:59 GMT 2025
|
PRIMARY | |||
|
613792
Created by
admin on Mon Mar 31 18:06:59 GMT 2025 , Edited by admin on Mon Mar 31 18:06:59 GMT 2025
|
PRIMARY | |||
|
100000082016
Created by
admin on Mon Mar 31 18:06:59 GMT 2025 , Edited by admin on Mon Mar 31 18:06:59 GMT 2025
|
PRIMARY | |||
|
DTXSID90149154
Created by
admin on Mon Mar 31 18:06:59 GMT 2025 , Edited by admin on Mon Mar 31 18:06:59 GMT 2025
|
PRIMARY | |||
|
72180
Created by
admin on Mon Mar 31 18:06:59 GMT 2025 , Edited by admin on Mon Mar 31 18:06:59 GMT 2025
|
PRIMARY | |||
|
SUB08550MIG
Created by
admin on Mon Mar 31 18:06:59 GMT 2025 , Edited by admin on Mon Mar 31 18:06:59 GMT 2025
|
PRIMARY | |||
|
7654
Created by
admin on Mon Mar 31 18:06:59 GMT 2025 , Edited by admin on Mon Mar 31 18:06:59 GMT 2025
|
PRIMARY | |||
|
CHEMBL501916
Created by
admin on Mon Mar 31 18:06:59 GMT 2025 , Edited by admin on Mon Mar 31 18:06:59 GMT 2025
|
PRIMARY | |||
|
LODENOSINE
Created by
admin on Mon Mar 31 18:06:59 GMT 2025 , Edited by admin on Mon Mar 31 18:06:59 GMT 2025
|
PRIMARY | |||
|
C073072
Created by
admin on Mon Mar 31 18:06:59 GMT 2025 , Edited by admin on Mon Mar 31 18:06:59 GMT 2025
|
PRIMARY | |||
|
C1499
Created by
admin on Mon Mar 31 18:06:59 GMT 2025 , Edited by admin on Mon Mar 31 18:06:59 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
gag protein expression; protection from cytopathogenic effects of HIV-1 or -2; anti-HIV-1 activity
IN-VITRO
|
||
|
METABOLITE ACTIVE -> PARENT |
IN-VITRO
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |